Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

The aim of this study was to investigate formoterol, an inhaled long-acting β2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 µg b.i.d.) or placebo via Turbuhaler® for 12 weeks. Symptoms were recorded daily. Spirometry and the incremental shuttle walking test (SWT) were performed at clinic visits. Compared with placebo, 18 µg b.i.d. formoterol reduced the mean total symptom score by 13% and increased the percentage of nights without awakenings by 15%. Formoterol (9 and 18 µg b.i.d.) significantly reduced symptom scores for breathlessness (−7% and −9%, respectively) and chest tightness (−11% and −8%, respectively), reduced the need for rescue medication (−25% and −18%, respectively), and increased symptom-free days (71% and 86%, respectively). FEV1 improved significantly after all three doses of formoterol (versus placebo). No differences were found between groups in SWT walking distance. No unexpected adverse events were seen. In conclusion, 9 and 18 µg b.i.d. formoterol reduced symptoms and increased the number of symptom-free days in a dose-dependent manner in chronic obstructive pulmonary disease patients. Formoterol improved lung function at a dose of 4.5 µg b.i.d. and higher.

[1]  G. Borg.  Psychophysical bases of perceived exertion. , 1982, Medicine and science in sports and exercise.

[2]  M. S. Singh,et al.  Development of a shuttle walking test of disability in patients with chronic airways obstruction. , 1992, Thorax.

[3]  A. Hardman,et al.  The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. , 1999, Thorax.

[4]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[5]  M. Morgan,et al.  A short outpatient pulmonary rehabilitation programme: immediate and longer-term effects on exercise performance and quality of life. , 1998, Respiratory medicine.

[6]  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. , 1997, Thorax.

[7]  C. Westermann,et al.  Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[8]  B. Wittekamp,et al.  List of investigators , 2003 .

[9]  J. Martin,et al.  Effect of nutritional status on exercise performance in patients with chronic obstructive pulmonary disease. , 1989, The American review of respiratory disease.

[10]  B. Lipworth,et al.  Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. , 1996, Thorax.

[11]  R. N. Brogden,et al.  Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. , 1998, Drugs.

[12]  D. O’Donnell,et al.  Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? , 2000, Chest.

[13]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[14]  T. Petty.  The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. , 1990, Chest.

[15]  M. Belman,et al.  Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[16]  S. Hurd,et al.  The impact of COPD on lung health worldwide: epidemiology and incidence. , 2000, Chest.

[17]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[18]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[19]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[20]  D. Taylor,et al.  The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. , 1985, The American review of respiratory disease.

[21]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[22]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[23]  B. Lipworth,et al.  Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[24]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[25]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[26]  H. Magnussen,et al.  Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[27]  A. Leitch.  The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease. , 1992, Respiratory medicine.

[28]  H. D. Short,et al.  Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. , 1987, The American review of respiratory disease.